Samsung Bioepis和AffaMed Therapeutics研发的依库珠单抗生物仿制药候选药物获得中国新药临床研究批准，进一步扩展进行中的全球三期临床试验
January 10, 2020 00:17 ET
|
C-Bridge Capital
SB12（即AMT904）是依库珠单抗生物仿制药的候选药物，用于治疗阵发性夜间血红蛋白尿唯一获得中国新药临床研究批准的舒立瑞®（依库珠单抗）1的生物仿制药候选药物 韩国仁川和中国上海, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis和AffaMed...
Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 Trial
January 09, 2020 19:33 ET
|
CBC Group
SB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuria The only biosimilar candidate referencing Soliris® (eculizumab)1 to be...
UPDATE – AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901
December 10, 2019 11:37 ET
|
CBC Group
SHANGHAI, China, Dec. 10, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a biopharmaceutical company founded and funded by CBC Group, a healthcare private equity firm focused on the development and...
AffaMed Therapeutics获得中国药监局批准，可在中国开展赫赛汀（曲妥珠单抗）的候选生物仿制药AMT901的临床试验
December 10, 2019 00:31 ET
|
C-Bridge Capital
中国上海, Dec. 10, 2019 (GLOBE NEWSWIRE) -- 由专注于医疗行业成长期和后期阶段投资机会的私募股权投资基金CBC Group出资成立的生物制药公司AffaMed...
AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901
December 10, 2019 00:31 ET
|
CBC Group
SHANGHAI, China, Dec. 10, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a biopharmaceutical company founded and funded by CBC Group, a healthcare private equity firm focused on the development and...
CBC Group 委任 Kerry Blanchard (PhD, MD) 為營運合夥人
November 12, 2019 06:04 ET
|
C-Bridge Capital
紐約, Nov. 12, 2019 (GLOBE NEWSWIRE) -- CBC Group 是一家私募股權公司，專注全球醫療保健市場的育成、收購和後期增長投資機會，今天宣佈委任行業資深人士 Kerry Blanchard (PhD, MD) 為營運合夥人。Blanchard 博士將在此職位上支援 CBC Group 投資組合公司管理團隊執行其價值創造計劃。 CBC Group 行政總裁...
CBC Group Appoints Kerry Blanchard, PhD, MD, as Operating Partner
November 11, 2019 23:08 ET
|
CBC Group
NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- CBC Group, a private equity firm focused on incubation, buyout and late-stage growth investment opportunities within the global healthcare market,...
Everest Medicines任命陈文德先生为首席商务官
May 10, 2019 09:00 ET
|
C-Bridge Capital
上海和纽约, May 10, 2019 (GLOBE NEWSWIRE) -- Everest Medicines今天宣布任命制药行业资深人士陈文德先生为其首席商务官。Everest Medicines 是一家专注于针对大中华及亚洲其它地区的患者之医疗需求的生物制药研发及商业化公司。在担任首席商务官的同时，陈文德也将担任康桥资本（CBC Group，前英文名C-Bridge...
Everest Medicines Appoints Wende Chen as Chief Commercial Officer
May 10, 2019 09:00 ET
|
C-Bridge Capital
SHANGHAI, China and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...
C-Bridge Capital成立AffaMed Therapeutics以加快中國生物製劑的商業化進程
February 12, 2019 11:39 ET
|
C-Bridge Capital
中國上海, Feb. 13, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics為一間新的生物製藥公司，由C-Bridge Capital出資成立。C-Bridge Capital是一間醫療行業的私人股本公司，專注於成長期和後期階段的投資機會。AffaMed Therapeutics今天宣佈與Samsung...